Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncimmune Ltd.

www.oncimmune.co.uk

Latest From Oncimmune Ltd.

Breakthrough Status, Big Investments For Liquid Biopsies

The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.

Diagnostics Commercial

Biodesix Buys US Laboratory Assets From Oncimmune

Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.

M & A Deals

Device Debut: Oncimmune Pushes Liver Cancer Test In The US

Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.

Approvals Research & Development

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

In Vitro Diagnostics Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oncimmune Ltd.
  • Senior Management
  • Adam Hill, PhD, CEO
    Matthew Hall, CFO
    Tariq Sethi, PhD, CSO
    Matthew Luttrell, Chief Commercial Officer
  • Contact Info
  • Oncimmune Ltd.
    Phone: 115 8231869
    Clinical Sciences Bldg. Nottingham Hosp.
    Hucknall Hall
    Nottingham, NG5 1PB
    UK
UsernamePublicRestriction

Register